Peter Lin MD, CCFP
Director, Primary Care Initiatives, Canadian Heart Research Centre, Ontario, CanadaDr. Peter Lin began his studies in the Faculty of Science and Engineering at the University of Toronto in Toronto, Ontario. Midway through, he moved to the Faculty of Medicine, where he completed his studies and became involved in research. Over the years, it became apparent to him that there was a wide chasm between research and clinical practice, and he moved into clinical practice in primary care and eventually into teaching in order to help bridge this gap. He served as the medical director at the Health & Wellness Centre, University of Toronto Scarborough, for 7 years.
Currently, Dr. Peter Lin is the Director of Primary Care Initiatives at the Canadian Heart Research Centre. He is also a contributing author to the Canadian Diabetes Guidelines 2013 and 2018 on the vascular protection section. He is also Associate Editor for the Elsevier WebPortal - PracticeUpdate Primary Care. He lectures and speaks internationally on a variety of topics. Dr. Lin has worked with KDIGO in order to help improve care for CKD patients. He has also been tracking and providing information on COVID-19 to the public since the beginning of the pandemic. Dr. Lin received a teaching award from the College of Family Physicians in 2011.
Disclosures
Dr. Lin has consulted with the following companies on Continuing Medical Education programs:Astrazeneca, Boeringher Ingelheim, Bayer, Eli Lilly, Amgen, Janssen, Merck, Pfizer, Sanofi, Abbott, HLS Therapeutics Inc.
No clinical trials. No patents.
Recent Contributions to PracticeUpdate:
- Prognostic Value of Fasting vs Non-Fasting LDL Levels on Long-Term Mortality
- NSAIDs and Cardiovascular Outcomes in Women
- Extended-Release Niacin With Laropiprant in High-Risk Patients
- Aldosterone-Renin Ratio in the Assessment of Primary Aldosteronism
- Ethnic-Specific Obesity Cutoffs for Diabetes Risk
- Statins and the Risk for Diabetes
- Epidemiological Ramifications of Diagnosing Diabetes With HbA1c Levels
- Empagliflozin Effective, Safe With Insulin for Inadequately Controlled Diabetes
- The Child or Adolescent With Elevated Blood Pressure
- Risks Linked to Systolic and Diastolic Hypertension Are Age-Dependent